Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- α versus toxicity after melphalan alone

This publication has 16 references indexed in Scilit:

• Isolated limb perfusion with tumour necrosis factor-α and melphalan with or without interferon-γ; for the treatment of in-transit melanoma metastases
  Melanoma Research, 1999
• Isolated Limb Perfusion with Tumor Necrosis Factor and Melphalan for Limb Salvage in 186 Patients with Locally Advanced Soft Tissue Extremity Sarcomas
  Annals of Surgery, 1996
• Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial.
  Journal of Clinical Oncology, 1996
• Thirty-five years of isolated limb perfusion for melanoma: Indications and results
  British Journal of Surgery, 1996
• Determinants of acute regional toxicity following isolated limb perfusion for melanoma
  Melanoma Research, 1996
• Long-term Morbidity After Regional Isolated Perfusion With Melphalan for Melanoma of the Limbs
  Archives of Surgery, 1995
• Patient- and treatment-related factors associated with acute regional toxicity after isolated perfusion for melanoma of the extremities
  The American Journal of Surgery, 1994
• In transit metastases of malignant melanoma treated by high dose rTNFα in combination with interferon-γ and melphalan in isolation perfusion
  World Journal of Surgery, 1992
• High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma.
  Journal of Clinical Oncology, 1992
• Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions
  European Journal of Cancer and Clinical Oncology, 1982